PMV Pharmaceuticals, Inc. (PMVP)

USD 1.49

(-1.97%)

Market Cap (In USD)

77.1 Million

Revenue (In USD)

-

Net Income (In USD)

-68.96 Million

Avg. Volume

322.51 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.4-3.47
PE
-
EPS
-
Beta Value
1.484
ISIN
US69353Y1038
CUSIP
69353Y103
CIK
1699382
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David H. Mack Ph.D.
Employee Count
-
Website
https://www.pmvpharma.com
Ipo Date
2020-09-25
Details
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.